LIVINGSTONE HEALTH HOLDINGS LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 200404283C)

PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 98,389,689 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY WITH UNLISTED WARRANTS ("RIGHTS CUM WARRANTS ISSUE")

- **RESULTS OF THE RIGHTS CUM WARRANTS ISSUE**

1. INTRODUCTION

1.1. The board of directors ("**Board**" or "**Directors**") of Livingstone Health Holdings Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 27 March 2024, 30 April 2024, 13 May 2024, 30 May 2024, 11 June 2024 and the offer information statement dated 11 June 2024 (the "**Offer Information Statement**") in relation to, *inter alia*, the Rights cum Warrants Issue.

1.2. Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as ascribed to them in the Offer Information Statement. Any reference to the time of day herein shall be a reference to Singapore time.

2. RESULTS OF THE RIGHTS CUM WARRANTS ISSUE

1.1. The Board wishes to announce that, as at the Closing Date on 27 June 2024, valid acceptances and excess applications were received for the following number of Rights Shares with Warrants:

	Number of Rights Shares with Warrants	**As a percentage of total number of the Rights Shares with Warrants available under the Rights cum Warrants Issue**
Valid Acceptances	78,575,896	79.86%
Excess Applications	14,688,042	14.93%
Total	**93,263,938**	**94.79%**

1.2. The valid acceptances include the acceptances of 56,789,853 Rights Shares with Warrants from the Undertaking Shareholders pursuant to the Irrevocable Undertakings.

1.3. The provisional allotments of the 19,813,793 Rights Shares with Warrants which were not validly accepted or subscribed for by the Entitled Shareholders, their renouncees and/or Purchasers under the Rights cum Warrants Issue, will be allocated to satisfy the valid excess applications for the Rights Shares with Warrants. As there are more Rights Shares with Warrants available for excess applications than the number of Excess Right Shares with Warrants applied, applicants with valid application of Excess Rights Shares with Warrants will also be allocated in full for such applications.

1.4. A total of 15,300 "nil-paid" Rights for the Rights Shares with Warrants which would otherwise have been provisionally allotted to Foreign Shareholders have been sold on the SGX-ST during the nil-paid rights trading period as provided in the Offer Information Statement. The net proceeds of such sales (after deduction of all expenses therefrom) will be pooled and thereafter distributed to Foreign Shareholders in proportion to their respective shareholdings or, as the case may be, the number of Shares standing to the credit of their respective Securities Accounts as at the Record Date and sent to them at their own risk by ordinary post, or in such other manner as they may have agreed with CDP for payment of any cash distributions. If the amount of net proceeds to be distributed to any single Foreign Shareholder is less than S$10.00, the Company shall be entitled to retain or deal with such net proceeds as the Directors may, in their absolute discretion, deem fit in the interests of the Company and no Foreign Shareholder or persons acting to the account or benefit of any such persons shall have any claim whatsoever against the Company, the Directors, the Sponsor, CDP, the Share Registrar and/or their respective officers in connection therewith.

2. REFUND FOR INVALID OR UNSUCCESSFUL ACCEPTANCES AND EXCESS APPLICATIONS

Monies accompanying invalid acceptances of and/or excess applications for Rights Shares with Warrants will be refunded without interest or any share of revenue or other benefit arising. Please refer to the details as set out at paragraphs 1.3, 2.4, 5.3 and 5.4 of Appendix III of the Offer Information Statement, paragraphs 3.1, 3.3, 4.2 and 5.4 of Appendix IV, and paragraphs 7, 14 and 18 of Appendix V of the Offer Information Statement for further information.

3. NET PROCEEDS FROM THE RIGHTS CUM WARRANTS ISSUE

3.1. After deducting estimated costs and expenses of approximately S$0.22 million incurred in connection with the Rights cum Warrants Issue, the Company has raised Net Proceeds of approximately S$1.27 million from the Rights cum Warrants Issue (excluding proceeds to be raised from the exercise of the Warrants). In line with the information disclosed in the Offer Information Statement, the Company intends to utilise the Net Proceeds (excluding proceeds to be raised from the exercise of the Warrants) in the following manner:

Purpose	Amount (S$)	Percentage Allocation (%)
Business growth, acquisition and expansion	518,000	40.72
General working capital requirements	754,000	59.28
Total	1,272,000	**100**

3.2. Pending deployment of the Net Proceeds for the purposes stated, the Net Proceeds will be deposited with banks and/or financial institutions, invested in short-term money markets or marketable securities or used for other purposes on a short-term basis as the Directors may, in their absolute discretion, deem fit in the interests of the Group.

4. ISSUE AND LISTING OF THE RIGHTS SHARES WITH WARRANTS

4.1. The Company expects that the 93,263,938 Rights Shares and the 93,263,938 Warrants will be allotted and issued on or about 3 July 2024 pursuant to the Rights cum Warrants Issue. The Warrants issued shall not be listed on the Catalist board of the SGX-ST or any other stock exchange. Each Warrant entitles the Warrantholder thereof to subscribe for one (1) New Share at the Exercise Price, subject to the terms and conditions set out in the Deed Poll.

4.2. The Rights Shares and the New Shares (when issued upon the exercise of the Warrants) will, upon allotment and issuance, rank *pari passu* in all respects with the then existing Shares for any dividends, rights, allotments or other distributions, the record date for which falls on or after the date of allotment and issue of the Rights Shares or date of issue of the New Shares (as the case may be), save as may be otherwise provided in the Deed Poll.

4.3. The Company will release an announcement to advise Shareholders on the date for the listing of and quotation of the 93,263,938 Rights Shares on the Catalist of the SGX-ST in due course, which is expected to be listed and quoted on the Catalist of the SGX-ST on or about 5 July 2024 and trading of such Rights Shares will commence with effect from 9.00 a.m. on or about 5 July 2024.

4.4. The Board wishes to take this opportunity to thank all Shareholders for their continued support in enabling the successful completion of the Rights cum Warrants Issue.

By Order of the Board

Dr Tay Ching Yit, Wilson
Executive Director and Chief Executive Officer
2 July 2024

---

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-00, AIA Tower, Singapore 048542